Dublin-listed Merrion Pharmaceuticals has reported narrower pre-tax losses of €2.2m for the first half of this year. This compares with €4.9m in the same period last year.
Revenues grew from €13,000 to just over €350,000, mainly from development fees from partnership agreements.
The company increased its spending on research and development by 5% to €1.7m.
Merrion specialises in developing tablets and capsules for drugs that have poor absorption and are generally given by injection.
